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Purpose: Bioengineering aims to produce  functional tissue replacements to repair defects and has 
been widely investigated over the past few decades. We aimed to review the available literature on the 
application of tissue engineering in ophthalmology, with a particular focus on ophthalmic plastic 
surgery and potential applications for eyelid reconstruction. 
Methods: A literature search was performed on the MEDLINE database using the keywords 
“bioengineering,” “tissue engineering,” and “ophthalmology.” Articles written in English were 
included. 
Results: There is a substantial body of work on tissue engineering of the cornea. Other structures in 
ophthalmology investigated include the conjunctiva, lacrimal gland, and orbital bone. We also discuss 
the potential application of tissue engineering in eyelid reconstruction. 
Conclusion: Tissue engineering represents the future of regenerative and reconstructive medicine, 
with significant potential applications in ophthalmic plastic surgery. 
 
 
Bioengineering represents the future of reconstructive medi- cine, but there are few studies that 
investigate the role of bioengineering in ophthalmic plastic surgery. We have sum- marized the key 
components of bioengineering below, with a focus on cellular scaffolds for tissue replacement. We 
review the available literature on its application in ophthalmology includ- ing corneal replacement, 
conjunctival repair, dry eye disease, and orbital fracture repair and focus on the potential applica- 
tions in the eyelid. 
Tissue engineering refers to the synthesis of living tis- sues using bioreactors, cells, scaffolds, 
and/or growth factors with the aim of creating a functional tissue replacement to repair defects. The 
use of engineered 3-dimensional (3D) biomaterial constructs to reconstruct or repair living tissue has 
been widely investigated over the last 2 decades.1–3 Ideally, bioengineered tissue would restore key 
functions of missing or defective tis- sues and would degrade at a rate which best complements    the 
natural rate of cellular differentiation and proliferation, 
 
ultimately integrating well with surrounding native tissue both in the immediate and long-term 
period. The basic principle of tissue engineering generally involves the combination of a poly- mer 
scaffold with a stem cell or precursor cell population. Key components required for successful tissue 
engineering include a viable scaffold, cells, stimulating factors to encourage desired cell behavior, 
and a blood supply. Figure demonstrates the basic principles of tissue engineering. 
The use of a porous scaffold to provide support and facilitate synthesis of 3D tissue represents 
 
one of the principal methods of tissue engineering. The role of the scaffold includes supporting and 
guiding cell attachment and tissue growth, pro- viding mechanical support and maintaining the space 
for new tissue to develop. Key scaffold characteristics therefore include 3D structure with adequate 
porosity, biocompatibility, biome- chanical likeness, and biodegradability.4 Both the chemical and 
physical properties of scaffolds are thus important in determin- ing their efficacy. Significant scaffold 
design criteria include material selection, biocompatibility, biodegradability, degra- dation profile 
(rate, by products, and strength characteristics), porosity (pore sizes, interconnections, and volume 
fraction), surface chemistry, topography, and cell–surface interactions.5 As tissue and cell properties 
vary significantly around the body, the design of tissue engineering strategies including suitable 
scaffolds needs to be specific to the tissue type being targeted. The mechanical properties of 
bioengineered scaffolds vary sig- nificantly depending on architecture,6 and studies have dem- 
onstrated that the interaction between cells and a scaffold can change depending on biomechanical 
properties.7 Therefore, it is important to understand the mechanics of this tissue in its native state to 
design suitable scaffolds for engineering this tissue. 
Both synthetic and natural biopolymers may be  used for tissue engineering of soft tissues. The 
most commonly used polymers include polylactic acid, polyglycolic acid, and a combination of the 
two, poly(lactic-co-glycolic) acid (PLGA). Poly(lactic-co-glycolic) acid is a biodegradable synthetic 
poly- ester which is approved by the US Food and Drug Administration for human clinical use. 
Poly(lactic-co-glycolic) acid has been extensively investigated for uses in tissue engineering due to 
the versatility in fabrication and range of achievable chemical and mechanical properties.8–10 
Numerous strategies have been devel- oped to modify the surfaces of polymers like PLGA to improve 
their cell and tissue interactions and moderate the inflamma- tory reactions that occur when 
biomaterials are placed in the body.11–13 
Natural polymers may also be used to create tissue engi- neering scaffolds and hydrogels. 
Commonly used natural poly- mers include chitosan, collagen, gelatin, silk fibrin, elastin, and 







Basic concept of tissue engineering involves the creation of a three-dimensional scaffold over 
which a precursor cell population is cultured. 
 
provide favorable cell-binding sites and are often degraded through natural metabolic pathways in the 
body. Naturally derived polymers such as chitosan, possibly in combination with synthetic polymers 
for improved strength, have potential as tissue engineering scaffolds for soft tissues due to their bio- 
mimetic properties. Although known for their ease in forming macroporous structures, natural 
polymers such as chitosan can be limited in their mechanical stability. Cross-linking chito- san 
structures has been shown to improve stability of resultant scaffolds.5 
More recently, foam-like material termed 3D graphene has been investigated as a potential 
scaffold material for tis- sue engineering.18 Studies have since demonstrated high cell viability and 
enhanced oxygenation due to its highly porous structure.19 
 
TISSUE ENGINEERING IN OPHTHALMOLOGY 
Thus far there have been promising studies investigating to role of cellular and acellular bioengineered 
scaffolds to replace native tissue in corneal disease, conjunctival reconstruction, dry eye disease, and 
orbital fracture repair. These are discussed in more detail below. 
 
Corneal Substitutes. Tissue engineering has long been investigated as an alternative to human 
corneal transplantation to treat potentially blinding corneal disease. There have been numerous studies 
of acellular polymer matrices aimed at promoting re-epithelialization in vivo. A number of groups 
have used Type I collagen scaffolds as artificial corneal extracellular matrices.4,14 Griffith and 
 
 
colleagues20 have conducted a number of studies using fibrillar recombinant human collagen Type I 
and III (RHCI or RHCIII) as corneal stromal matrices. RHCIII was found to be optically superior, 
and the group was later successful in implanting 10 cell-free corneal substitutes into human patients 
made  with  RHCIII and cross-linked with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-
hydroxysuccinimide. After 6 to 7 months, the substitutes were well integrated with regeneration of 
corneal epithelium, stroma, and nerves, although long-term outcomes are unknown.15,21 More 
recently, Zhang et al.22 studied a novel collagen scaffold synthesized with rat tail 
 
 
collagen I for use as a potential corneal tissue substitute for  use in corneal transplantation. The 
scaffold was found to have comparable transmittance and thickness when compared with human 
cornea. Furthermore, the scaffold was successful in supporting reepithelialization and keratocyte  
cellularization  ex vivo using porcine corneal epithelial cells. 
Insler et al.23 first reported the concept of corneal endo- thelial cell transplant expanded ex vivo 
onto collagen-coated dextran in 1990, and since then there have been many studies of corneal 
endothelial cell culture. Liang and colleagues24 devel- oped a novel chitosan-based scaffold onto 
which they were suc- cessful in establishing corneal endothelial cell culture derived from rabbits ex 
vivo. Following implantation into Wistar rab- bits, the blended membranes demonstrated good 
histocompat- ibility and degraded steadily with less associated inflammation compared with control. 
Similarly, Ozcelik et al.25 fabricated an ultrathin chitosan-poly(ethylene glycol) hydrogel film, which 
was found to be >95% optically transparent and able to support sheep corneal endothelial cell culture. 
Combinations of chito- san including keratin–chitosan and polycaprolactone–chitosan membranes 
have also been studied in vitro and been shown to support cell culture.26,27 
Lai et al.17,28,29 studied the use of corneal endothelial cell sheets fabricated with hydrogel carriers 
resembling the native corneal endothelium, which aimed to minimize some of the issues encountered 
with existing corneal endothelial substrates including optical interference, foreign body reaction, and 
dis- turbance of physiologic function. Initially working with gela- tin hydrogels, the authors recently 
investigated hydrogels made using hyaluronic acid, a biopolymer which is naturally found  in the 
aqueous and vitreous. They found that cell sheet trans- plantation using these hydrogels resulted in 
superior biologic stability with minimal adverse effects in rabbit studies.16 In an attempt to further 
improve the properties of collagen hydrogels, Takezawa et al.30,31 developed a collagen vitrigel with 
the key step of vitrification allowing water to evaporate in a controlled manner with resultant cross-
linking and rearrangement of col- lagen fibrils. The group later studied the ability of collagen vit- 
rigel to support the 3 main corneal cell layers, limbal explants, keratocytes, and endothelial cells, with 






Graphene has also been studied as a potential biomaterial for use in the cornea, with Tan et al.33 
culturing human corneal stromal fibroblasts onto graphene films for use as a synthetic keratoprosthesis 
skirt material. 
 
Conjunctival Reconstruction. There have  been  a  few  studies investigating the  use  of  tissue-
engineered  implants  in conjunctival reconstruction. Hsu et al.34 grafted porous collagen–
glycosaminoglycan copolymer matrices into the bulbar conjunctiva of rabbits with artificial full-
thickness conjunctival wounds. The authors found that by 28 days, the rabbits with matrix grafts had 
less wound contraction (6.8% ± 3.2% fornix shortening) compared with controls who were ungrafted 
(26.4% 
± 5% fornix shortening). Lee et al.35 later studied the use of modified PLGA 50/50 scaffolds modified 
with either hyaluronic acid or amniotic membrane in conjunctival reconstruction. The authors used 
human stromal fibroblasts obtained from human corneal tissues and were successful in seeding 
scaffolds prior to implantation in albino rabbits. At 4 weeks postoperative, grafted wounds were found 
to contract 6% compared with 25% of ungrafted conjunctival wounds. In addition to their use in the 
cornea, collagen vitrigels have also been studied in conjunctival reconstruction.36 Zhou et al.37 
demonstrated that optimized vitrified collagen was able to successfully promote conjunctival epithelial 
cell growth and goblet cell repopulation during in vitro rabbit studies. 
 
Dry Eye. There have also been a number of studies aimed     at  creating  a  tissue-engineered  tear  
secretory  device  to treat patients with keratoconjunctivitis sicca who remain symptomatic despite 
conventional treatment. Many previous groups have reported successful animal and human cell culture 
onto basic extracellular matrices with collagen I and Matrigel (Corning Incorporated, NY, USA),38–40 
a preparation derived from basement membranes of the Engelberth-Holm-Swarm mouse sarcoma line 
containing laminin, collagen IV, heparin- sulfate proteoglycans, entactin, and nidogen.41 Selvam and 
colleagues42 have also since shown culture of purified rabbit lacrimal acinar cells onto numerous 
matrix protein-coated polymers including copolymers of PLGA (85:15 and 50:50) and  poly-l-lactic  
acid  with  retention  of  secretory  properties. These copolymers, as discussed previously, have the 
advantages of having adjustable biomechanical properties and the ability to be tailored to specific 
target tissues. 
In a review of bioengineering for conjunctiva and dry eye, Lu et al.36 discussed the potential use 
of “organ-on-a-chip” tech- nology for the ocular surface. Organ-on-a-chip refers to a bioen- gineered 
microdevice with cultured cells in an attempt to mimic target organ function, and some success has 
been reported with lung, liver, intestine, spleen, and bone marrow studies.43–47 Any successful tear 
 
 
secretory unit would require lacrimal gland cells, conjunctival epithelium, and microfluid channels, 
and prelimi- nary in vitro studies of conjunctival epithelium and artificial lacrimal glands provide a 
basis for further development.48,49 
 
Orbital Fractures and Orbital Bone Engineering. The orbital floor is the most commonly affected 
wall of the orbit in trauma, and posttraumatic changes can manifest in enophthalmos and diplopia. 
Restoration of orbital volume is therefore vital in preventing complications and maintaining normal 
globe function. There are numerous implant options for use during orbital wall repair, of which 
autologous bone graft remains the gold standard, although with the obvious limitation of donor site 
morbidity and harvesting challenges. As such, various biomaterials have been 
 
 
developed, and include nonresorbable alloplastic, resorbable alloplastic, and more recently, 
bioengineered bone. Nonresorbable material studied in the past includes titanium mesh, porous 
polyethylene (Medpor Stryker, Kalamazoo, MI, USA), and bioactive glass.50 Notable risks of 
nonresorbable material include foreign body reaction, migration, and infection.51 To address some of 
these issues, biodegradable polymers have been studied as alternative options. Poly(lactic acid), PLGA, 
and combinations of and derivatives of the two have been studied extensively in the past, and there 
have also been studies of polyglactin-910 mesh and a newer periosteum–polymer composite 
material.50,52 Kontio et al.53 compared polydioxanone and poly(l/d)lactide  implants in rat studies and 
found that polydioxanone was mechanically unsuitable, losing form within 2 months but the 
poly(l/d)lactide polymers showed promising results at 7 months follow up. The group then progressed 
to human studies using poly(l/d)lactide 70/30 and found that the bioresorbable implants resulted in 
good clinical outcomes for patients with 2 cm2 or larger defects with 36 weeks of follow up.51 The 
authors then compared outcomes with fractures repaired using autologous bone graft and found no 
statistically significant differences in complications.54 However, long-term outcomes of resorbable 
implants are not well described, and suitability of use may depend on fracture size.50 
There have been a number of recent studies investigating the potential for orbital bone tissue 
engineering after previous established studies for bone regeneration of the mandible, cra- nium, and 
limbs.55–57 Mesenchymal stem cells have been the most widely investigated cell line for craniofacial 
tissue engineering and have been shown to proliferate well in vitro from small sam- ples.58 
Additionally, there is a growing body of work surrounding bone morphogenetic proteins , which secrete 
signaling molecules stimulating differentiation of osteoprogenitor cells and thereby bone formation.59 
Currently, bone morphogenetic protein type 2 and 7 have been developed for clinical applications.60,61 
Recent advances have used biodegradable 5-ethyl-5(hydroxymethyl)- b,b-dimethyl-1,3-dioxane-2-
ethanol (EH)–poly(ethylene glycol) (EH–PEG) hydrogels with integration of mesenchymal stems 
cells to deliver bone morphogenetic protein-2 to injured tissue.62 This is particularly of interest in 
orbital fracture repair, as the periosteum, which contains the osteoprogenitor and chondropro- genitor 
cells, is frequently injured in facial trauma, further delay- ing healing postfracture.63 Betz et al.62 
loaded EH-PEG with bone morphogenetic protein-2 and implanted them into 8-mm orbital floor 
defects in rabbits. The authors found that there was significant bone growth at 28 days, establishing 
the viability of this concept for future studies. Rohner et al.64 studied the use of polycaprolactone 
coated with bone marrow in pig orbital defects, which was shown to result in significantly more bone 
regenera- tion compared with polycaprolactone alone at 3 months postre- pair (14.1% vs. 4.5%). 
Medical grade polycaprolactone along with its composites created via fused deposition modeling has 
also been studied in orbital floor reconstruction with promising results in human patients.65,66 Other 
 
 
studies have focused more on craniofacial applications and include PLGA seeded with periosteal 
cells,64 polycaprolactone with cultured calvarial osteo- blasts and mesenchymal progenitor cells,67,68 
and poly(propylene fumarate) scaffolds treated with growth factor and infused with bone marrow.69 
Such tissue-engineered bone constructs therefore have the potential to provide not only immediate 
support and restoration of orbital volume but also long-term benefits due to early stimulation of bone 
regeneration. 
 
ROLE IN EYELID RECONSTRUCTION 
Eyelid reconstruction represents one of the most challenging areas of reconstructive plastic surgery 






of anatomical complexity, functional considerations, and aes- thetic concerns. Eyelid defects requiring 
reconstruction are commonly secondary to tumor excision, trauma, or congeni- tal defects. Full-
thickness eyelid defects that cannot be closed directly require reconstruction of both the anterior 
lamella, which consists of skin and the orbicularis oculi muscle, and  the posterior lamella, which 
includes the tarsal plate and pal- pebral conjunctiva.70 Among the most obvious  structures  to be 
bioengineered in eyelid is the tarsus, which is difficult to substitute and has excellent potential due to 
its thin structure. The tarsus provides both support and structural form, making  it an essential 
component of the eyelid’s function and physical appearance. Natural tarsus is a specialized tissue that 
features both dense fibrous connective tissue and typical cartilage. Structurally, tarsus consists of 
fibroblastic  cells  surrounded by an extracellular matrix with type I and III collagen, and aggrecan.71 
An understanding of the target tissue biomechanics rep- resents an important first step toward 
successful tissue engi- neering. Important parameters to consider when evaluating biomechanics of 
structures such as the tarsal plate include the following: the elastic modulus, tensile strength, and 
maximum strain. The elastic modulus refers to the measured strain in being deformed elastically and 
is defined as the slope of its stress–strain curve. The tensile strength is defined as the maxi- mum 
stress or strain a material can withstand before failing. The maximum strain refers to the total strain 
just prior to fail- ure during tensile strength testing. In the only previous study of the biomechanics of 
human tarsus, we found that fresh tar- sus tissue had a mean toe modulus of 0.14 (0.10) MPa, elastic 
modulus of 1.73 (0.61) MPa, extensibility of 15.8% (2.1%), and phase angle of 6.4° (2.4°). After  
adjusting  for  the  ini- tial tissue slack, the maximum strain ranged from 23.8% to 30.0%.72 
There is only one previous study investigating the use of engineered polymeric scaffolds for tarsal 
repair, which was con- ducted prior to our study of the normal tarsus biomechanics.73 This study used 
a type of polyhydroxyalkanoates as an acellular synthetic tarsal substitute in a rat study and found that 
they were successful in supporting eyelid reconstruction, fibroblast growth, and fibrous encapsulation. 
Polyhydroxyalkanoates are biode- gradable and thermoprocessable polyesters produced by micro- 
organisms.39,74 Poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) consisting of 12% mol% 3HHx were 
used to produce scaffolds with an average thickness of 0.7 mm and resultant micropores of 5 μm 
diameter. These scaffolds were cut into 1 mm × 1 mm pieces and implanted into the upper eyelids of 
3-month-old rats, with acellular dermal matrices of same size and thickness used as controls. 
Postoperative histologic studies demonstrated high density of inflammatory cell infiltrate around the 
poly(3- hydroxybutyrate-co-3-hydroxyhexanoate) scaffold in the first 2 weeks postoperatively 
compared with few inflammatory cells in the control group. At 8 weeks, the reaction had shifted to 
one of chronic inflammation, with ongoing macrophage and lym- phocyte infiltration with the 
 
 
percentage of fibroblasts 32.13% ± 1.47% versus 100% in the acellular dermal matrix group and 
unoperated rates.73 The significant inflammatory response dem- onstrated in this animal study suggests 
that further refinement is required to improve tolerability once implanted. 
In addition to numerous studied strategies to improve the biocompatibility of engineered 
scaffolds,11–13  cultured  native cells preimplantation onto the scaffolds also aims to reduce such 
inflammatory responses. Given the importance of fibroblasts within the histologic structure of tarsus, 





biocompatibility and also enhance the biomechanical proper- ties. The culture of lung fibroblasts is 
well established in the literature,75–78 and we have had success in replicating these studies with eyelid 
skin. Lung fibroblasts have been previously derived from lung tissue obtained at autopsy and cultured 
using Dulbecco’s modified Eagle’s medium (Life Technologies, Inc., Grand Island, NY) with various 
supplements at 37° in 10% carbon dioxide. Crystal violet staining along with immuno- fluorescent 
staining using a monoclonal antibody specific for human fibroblasts was used to confirm fibroblast 
culture.79 Using a similar method, we have been successful in establishing fibroblast culture using 
small samples of eyelid skin taken at the time of various oculoplastic procedures. We found that cell 
culture reached confluence within 4 weeks and immunofluores- cent staining of the cells in early 
passages labeled strongly for fibroblast-specific markers. We are currently working on stud- ies aimed 
at establishing fibroblast cell seeding onto artificial scaffolds constructed with biomechanical 
properties similar to human tarsus tissue. 
 
FUTURE CONSIDERATIONS 
Bioengineering represents the future of reconstructive medi- cine, and there may be significant 
potential for the application in ophthalmic plastic reconstructive surgery. 
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